Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/445—Non condensed piperidines, e.g. piperocaine
  • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
  • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/08—Bridged systems

Definitions

• DAG Diacylglycerol kinases
• PLCyl T cell receptor
• PIP3 phosphatidylinositol 4, 5-biphosphate
• IP3 is important in facilitating release of calcium from the endoplasmic reticulum
• DAG interacts with other proteins important in TCR signal transduction, such as Protein kinase CO and the Ras activating protein RasGRPI.
• proteins important in TCR signal transduction such as Protein kinase CO and the Ras activating protein RasGRPI.
• DGKalpha, DGKdelta, and DGKzeta three isoforms of DGK are known to be present within T cells (DGKalpha, DGKdelta, and DGKzeta) , only two, DGKalpha and DGKzeta, are thought to play an important role in facilitating DAG metabolism downstream of the TCR.
• DGKalpha and DGKzeta are viewed as targets for cancer immunotherapy (Riese M.J. et al., Front Cell Dev Biol. (2016) 4: 108; Chen, S.S. et al., Front Cell Dev Biol. (2016) 4: 130; Avila-Flores, A. et al., Immunology and Cell Biology (2017) 95: 549-563; Noessner, E., Front Cell Dev Biol. (2017) 5: 16; Krishna, S., et al., Front Immunology (2013) 4: 178; Jing, W. et al., Cancer Research (2017) 77: 5676-5686.
• Ring A is phenyl or 6-membered heteroaryl
• n 0-4;
• R 2 is hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, C 1 -C 6 heteroalkyl, cycloalkyl, or heterocycloalkyl;
• n 0-8;
• T is N or CR T ;
• R T is hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, or C 1 -C 6 heteroalkyl;
• p 0-4;
• each R a is independently C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, C 1 -C 6 heteroalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C 1 -C 6 alkylene (cycloalkyl) , C 1 -C 6 alkylene (heterocycloalkyl) , C 1 -C 6 alkylene (aryl) , or C 1 -C 6 alkylene (heteroaryl) , wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R;
• R a are taken together with the atom to which they are attached to form a heterocycloalkyl optionally substituted with one or more R;
• each R b is independently hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, C 1 -C 6 heteroalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C 1 -C 6 alkylene (cycloalkyl) , C 1 -C 6 alkylene (heterocycloalkyl) , C 1 -C 6 alkylene (aryl) , or C 1 -C 6 alkylene (heteroaryl) , wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R;
• R b are taken together with the atom to which they are attached to form a heterocycloalkyl optionally substituted with one or more R;
• R c and R d are each independently hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, C 1 -C 6 heteroalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C 1 -C 6 alkylene (cycloalkyl) , C 1 -C 6 alkylene (heterocycloalkyl) , C 1 -C 6 alkylene (aryl) , or C 1 -C 6 alkylene (heteroaryl) , wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R;
• R c and R d are taken together with the atom to which they are attached to form a heterocycloalkyl optionally substituted with one or more R;
• the compound is of Formula (Ia) :
• the compound is of Formula (Ib) :
• n’ is 0-3
• the compound is of Formula (Ic) :
• n’ is 0-3
• the compound is of Formula (Id) :
• n’ is 0-3
• the compound is of Formula (Ie) :
• n’ is 0-3
• the compound is of Formula (If) :
• each R 1a and R 1b are independently selected from R 1 .
• the compound is of Formula (Ig) :
• each R 1a and R 1b are independently selected from R 1 .
• Ring A is phenyl or 6-membered heteroaryl
• n 0-4;
• R 2 is hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, C 1 -C 6 heteroalkyl, cycloalkyl, or heterocycloalkyl;
• Ring B is a bicyclic ring
• n 0-8;
• p 0-4;
• each R a is independently C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, C 1 -C 6 heteroalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C 1 -C 6 alkylene (cycloalkyl) , C 1 -C 6 alkylene (heterocycloalkyl) , C 1 -C 6 alkylene (aryl) , or C 1 -C 6 alkylene (heteroaryl) , wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R;
• R a are taken together with the atom to which they are attached to form a heterocycloalkyl optionally substituted with one or more R;
• each R b is independently hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, C 1 -C 6 heteroalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C 1 -C 6 alkylene (cycloalkyl) , C 1 -C 6 alkylene (heterocycloalkyl) , C 1 -C 6 alkylene (aryl) , or C 1 -C 6 alkylene (heteroaryl) , wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R;
• R b are taken together with the atom to which they are attached to form a heterocycloalkyl optionally substituted with one or more R;
• R c and R d are each independently hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, C 1 -C 6 heteroalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C 1 -C 6 alkylene (cycloalkyl) , C 1 -C 6 alkylene (heterocycloalkyl) , C 1 -C 6 alkylene (aryl) , or C 1 -C 6 alkylene (heteroaryl) , wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R;
• R c and R d are taken together with the atom to which they are attached to form a heterocycloalkyl optionally substituted with one or more R;
• the compound is of Formula (IIa) :
• the compound is of Formula (IIb) :
• n’ is 0-3
• the compound is of Formula (IIc) :
• n’ is 0-3
• the compound is of Formula (IId) :
• n’ is 0-3
• the compound is of Formula (IIe) :
• n’ is 0-3
• composition comprising a compound disclosed herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
• Also disclosed herein is a method of inhibiting the activity of at least one of diacylglycerol kinase selected from diacylglycerol kinase alpha (DGKalpha) and diacylglycerol kinase zeta (DGKzeta) , in a subject in need thereof, the method comprising administering to the subject a compound disclosed herein, or a pharmaceutically acceptable salt thereof.
• DGKalpha diacylglycerol kinase alpha
• DGKzeta diacylglycerol kinase zeta
• Also disclosed herein is a method of inhibiting the activity of diacylglycerol kinase alpha (DGKalpha) , in a subject in need thereof, the method comprising administering to the subject a compound disclosed herein, or a pharmaceutically acceptable salt thereof.
• DGKalpha diacylglycerol kinase alpha
• Also disclosed herein is a method of a disease associated with aberrant diacylglycerol kinase signaling, in a subject in need thereof, the method comprising administering to the subject a compound disclosed herein, or a pharmaceutically acceptable salt thereof.
• the diacylglycerol kinase is diacylglycerol kinase alpha.
• the disease is cancer or a viral infection.
• the method further comprises administering an additional therapeutic agent.
• the additional therapeutic agent is an anti-cancer agent or an anti-viral agent.
• Carboxyl refers to -COOH.
• Cyano refers to -CN.
• Alkyl refers to a straight-chain, or branched-chain saturated hydrocarbon monoradical having from one to about ten carbon atoms, more preferably one to six carbon atoms. Examples include, but are not limited to methyl, ethyl, n-propyl, isopropyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl, 3-methyl-1-butyl, 2-methyl-3-butyl, 2, 2-dimethyl-1-propyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2, 2-dimethyl-1-butyl, 3, 3-dimethyl-1-butyl, 2-ethyl-1-butyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, isopent
• a numerical range such as “C 1 -C 6 alkyl” or “C 1-6 alkyl” means that the alkyl group may consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms, although the present definition also covers the occurrence of the term “alkyl” where no numerical range is designated.
• the alkyl is a C 1-10 alkyl.
• the alkyl is a C 1-6 alkyl.
• the alkyl is a C 1-5 alkyl.
• the alkyl is a C 1-4 alkyl.
• the alkyl is a C 1-3 alkyl.
• an alkyl group may be optionally substituted, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like.
• the alkyl is optionally substituted with oxo, halogen, -CN, -COOH, -COOMe, -OH, -OMe, -NH 2 , or -NO 2 .
• the alkyl is optionally substituted with halogen, -CN, -OH, or -OMe.
• the alkyl is optionally substituted with halogen.
• Alkenyl refers to a straight-chain, or branched-chain hydrocarbon monoradical having one or more carbon-carbon double-bonds and having from two to about ten carbon atoms, more preferably two to about six carbon atoms.
• a numerical range such as “C 2 -C 6 alkenyl” or “C 2-6 alkenyl” means that the alkenyl group may consist of 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms, although the present definition also covers the occurrence of the term “alkenyl” where no numerical range is designated.
• an alkenyl group may be optionally substituted, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like.
• the alkenyl is optionally substituted with oxo, halogen, -CN, -COOH, -COOMe, -OH, -OMe, -NH 2 , or -NO 2 .
• the alkenyl is optionally substituted with halogen, -CN, -OH, or -OMe.
• the alkenyl is optionally substituted with halogen.
• Alkynyl refers to a straight-chain or branched-chain hydrocarbon monoradical having one or more carbon-carbon triple-bonds and having from two to about ten carbon atoms, more preferably from two to about six carbon atoms. Examples include, but are not limited to ethynyl, 2-propynyl, 2-butynyl, 1, 3-butadiynyl and the like.
• a numerical range such as “C 2 -C 6 alkynyl” or “C 2-6 alkynyl” means that the alkynyl group may consist of 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms, although the present definition also covers the occurrence of the term “alkynyl” where no numerical range is designated.
• an alkynyl group may be optionally substituted, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like.
• the alkynyl is optionally substituted with oxo, halogen, -CN, -COOH, COOMe, -OH, -OMe, -NH 2 , or -NO 2 .
• the alkynyl is optionally substituted with halogen, -CN, -OH, or -OMe.
• the alkynyl is optionally substituted with halogen.
• Alkylene refers to a straight or branched divalent hydrocarbon chain. Unless stated otherwise specifically in the specification, an alkylene group may be optionally substituted, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, the alkylene is optionally substituted with oxo, halogen, -CN, -COOH, COOMe, -OH, -OMe, -NH 2 , or -NO 2 . In some embodiments, the alkylene is optionally substituted with halogen, -CN, -OH, or -OMe. In some embodiments, the alkylene is optionally substituted with halogen.
• Alkoxy refers to a radical of the formula -OR a where R a is an alkyl radical as defined. Unless stated otherwise specifically in the specification, an alkoxy group may be optionally substituted, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, the alkoxy is optionally substituted with halogen, -CN, -COOH, COOMe, -OH, -OMe, -NH 2 , or -NO 2 . In some embodiments, the alkoxy is optionally substituted with halogen, -CN, -OH, or -OMe. In some embodiments, the alkoxy is optionally substituted with halogen.
• Aryl refers to a radical derived from a hydrocarbon ring system comprising 6 to 30 carbon atoms and at least one aromatic ring.
• the aryl radical may be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may include fused (when fused with a cycloalkyl or heterocycloalkyl ring, the aryl is bonded through an aromatic ring atom) or bridged ring systems.
• the aryl is a 6-to 10-membered aryl.
• the aryl is a 6-membered aryl (phenyl) .
• Aryl radicals include, but are not limited to, aryl radicals derived from the hydrocarbon ring systems of anthrylene, naphthylene, phenanthrylene, anthracene, azulene, benzene, chrysene, fluoranthene, fluorene, as-indacene, s-indacene, indane, indene, naphthalene, phenalene, phenanthrene, pleiadene, pyrene, and triphenylene.
• an aryl may be optionally substituted, for example, with halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like.
• the aryl is optionally substituted with halogen, methyl, ethyl, -CN, -COOH, COOMe, -CF 3 , -OH, -OMe, -NH 2 , or -NO 2 .
• the aryl is optionally substituted with halogen, methyl, ethyl, -CN, -CF 3 , -OH, or -OMe. In some embodiments, the aryl is optionally substituted with halogen.
• Cycloalkyl refers to a partially or fully saturated, monocyclic, or polycyclic carbocyclic ring, which may include fused (when fused with an aryl or a heteroaryl ring, the cycloalkyl is bonded through a non-aromatic ring atom) , spiro, or bridged ring systems. In some embodiments, the cycloalkyl is fully saturated.
• Representative cycloalkyls include, but are not limited to, cycloalkyls having from three to fifteen carbon atoms (C 3 -C 15 fully saturated cycloalkyl or C 3 -C 15 cycloalkenyl) , from three to ten carbon atoms (C 3 -C 10 fully saturated cycloalkyl or C 3 -C 10 cycloalkenyl) , from three to eight carbon atoms (C 3 -C 8 fully saturated cycloalkyl or C 3 -C 8 cycloalkenyl) , from three to six carbon atoms (C 3 -C 6 fully saturated cycloalkyl or C 3 -C 6 cycloalkenyl) , from three to five carbon atoms (C 3 -C 5 fully saturated cycloalkyl or C 3 -C 5 cycloalkenyl) , or three to four carbon atoms (C 3 -C 4 fully saturated cycloalkyl or C 3 -C
• the cycloalkyl is a 3-to 10-membered fully saturated cycloalkyl or a 3-to 10-membered cycloalkenyl. In some embodiments, the cycloalkyl is a 3-to 6-membered fully saturated cycloalkyl or a 3-to 6-membered cycloalkenyl. In some embodiments, the cycloalkyl is a 5-to 6-membered fully saturated cycloalkyl or a 5-to 6-membered cycloalkenyl.
• Monocyclic cycloalkyls include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
• Polycyclic cycloalkyls include, for example, adamantyl, norbornyl, decalinyl, bicyclo [3.3.0] octane, bicyclo [4.3.0] nonane, cis-decalin, trans-decalin, bicyclo [2.1.1] hexane, bicyclo [2.2.1] heptane, bicyclo [2.2.2] octane, bicyclo [3.2.2] nonane, and bicyclo [3.3.2] decane, and 7, 7-dimethyl-bicyclo [2.2.1] heptanyl.
• Partially saturated cycloalkyls include, for example cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl.
• a cycloalkyl is optionally substituted, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like.
• a cycloalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -COOH, COOMe, -CF 3 , -OH, -OMe, -NH 2 , or -NO 2 .
• a cycloalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF 3 , -OH, or -OMe.
• the cycloalkyl is optionally substituted with halogen.
• Halo or “halogen” refers to bromo, chloro, fluoro or iodo. In some embodiments, halogen is fluoro or chloro. In some embodiments, halogen is fluoro.
• Haloalkyl refers to an alkyl radical, as defined above, that is substituted by one or more halo radicals, as defined above, e.g., trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl, 2, 2, 2-trifluoroethyl, 1, 2-difluoroethyl, 3-bromo-2-fluoropropyl, 1, 2-dibromoethyl, and the like.
• “Hydroxyalkyl” refers to an alkyl radical, as defined above, that is substituted by one or more hydroxyls. In some embodiments, the alkyl is substituted with one hydroxyl. In some embodiments, the alkyl is substituted with one, two, or three hydroxyls. Hydroxyalkyl include, for example, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, or hydroxypentyl. In some embodiments, the hydroxyalkyl is hydroxymethyl.
• Aminoalkyl refers to an alkyl radical, as defined above, that is substituted by one or more amines. In some embodiments, the alkyl is substituted with one amine. In some embodiments, the alkyl is substituted with one, two, or three amines. Aminoalkyl include, for example, aminomethyl, aminoethyl, aminopropyl, aminobutyl, or aminopentyl. In some embodiments, the aminoalkyl is aminomethyl.
• Heteroalkyl refers to an alkyl group in which one or more skeletal atoms of the alkyl are selected from an atom other than carbon, e.g., oxygen, nitrogen (e.g., -NH-, -N (alkyl) -) , sulfur, phosphorus, or combinations thereof.
• a heteroalkyl is attached to the rest of the molecule at a carbon atom of the heteroalkyl.
• a heteroalkyl is a C 1 -C 6 heteroalkyl wherein the heteroalkyl is comprised of 1 to 6 carbon atoms and one or more atoms other than carbon, e.g., oxygen, nitrogen (e.g.
• heteroalkyl is attached to the rest of the molecule at a carbon atom of the heteroalkyl.
• heteroalkyl are, for example, -CH 2 OCH 3 , -CH 2 CH 2 OCH 3 , -CH 2 CH 2 OCH 2 CH 2 OCH 3 , -CH (CH 3 ) OCH 3 , -CH 2 NHCH 3 , -CH 2 N (CH 3 ) 2 , -CH 2 CH 2 NHCH 3 , or -CH 2 CH 2 N (CH 3 ) 2 .
• a heteroalkyl is optionally substituted for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like.
• a heteroalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF 3 , -OH, -OMe, -NH 2 , or -NO 2 .
• a heteroalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF 3 , -OH, or -OMe. In some embodiments, the heteroalkyl is optionally substituted with halogen.
• Heterocycloalkyl refers to a 3-to 24-membered partially or fully saturated ring radical comprising 2 to 23 carbon atoms and from one to 8 heteroatoms selected from the group consisting of nitrogen, oxygen, phosphorous, silicon, and sulfur. In some embodiments, the heterocycloalkyl is fully saturated. In some embodiments, the heterocycloalkyl comprises one to three heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur. In some embodiments, the heterocycloalkyl comprises one to three heteroatoms selected from the group consisting of nitrogen and oxygen. In some embodiments, the heterocycloalkyl comprises one to three nitrogens. In some embodiments, the heterocycloalkyl comprises one or two nitrogens.
• the heterocycloalkyl comprises one nitrogen. In some embodiments, the heterocycloalkyl comprises one nitrogen and one oxygen.
• the heterocycloalkyl radical may be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may include fused (when fused with an aryl or a heteroaryl ring, the heterocycloalkyl is bonded through a non-aromatic ring atom) , spiro, or bridged ring systems; and the nitrogen, carbon, or sulfur atoms in the heterocycloalkyl radical may be optionally oxidized; the nitrogen atom may be optionally quaternized.
• heterocycloalkyls include, but are not limited to, heterocycloalkyls having from two to fifteen carbon atoms (C 2 -C 15 fully saturated heterocycloalkyl or C 2 -C 15 heterocycloalkenyl) , from two to ten carbon atoms (C 2 -C 10 fully saturated heterocycloalkyl or C 2 -C 10 heterocycloalkenyl) , from two to eight carbon atoms (C 2 -C 8 fully saturated heterocycloalkyl or C 2 -C 8 heterocycloalkenyl) , from two to seven carbon atoms (C 2 -C 7 fully saturated heterocycloalkyl or C 2 -C 7 heterocycloalkenyl) , from two to six carbon atoms (C 2 -C 6 fully saturated heterocycloalkyl or C 2 -C 6 heterocycloalkenyl) , from two to five carbon atoms (C 2 -C 5 fully saturated heterocycloalkyl or C 2 -C 5
• heterocycloalkyl radicals include, but are not limited to, aziridinyl, azetidinyl, oxetanyl, dioxolanyl, thienyl [1, 3] dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl
• heterocycloalkyl also includes all ring forms of the carbohydrates, including but not limited to the monosaccharides, the disaccharides, and the oligosaccharides.
• heterocycloalkyls have from 2 to 10 carbons in the ring. It is understood that when referring to the number of carbon atoms in a heterocycloalkyl, the number of carbon atoms in the heterocycloalkyl is not the same as the total number of atoms (including the heteroatoms) that make up the heterocycloalkyl (i. e. skeletal atoms of the heterocycloalkyl ring) .
• the heterocycloalkyl is a 3-to 8-membered heterocycloalkyl.
• the heterocycloalkyl is a 3-to 7-membered heterocycloalkyl. In some embodiments, the heterocycloalkyl is a 3-to 6-membered heterocycloalkyl. In some embodiments, the heterocycloalkyl is a 4-to 6-membered heterocycloalkyl. In some embodiments, the heterocycloalkyl is a 5-to 6-membered heterocycloalkyl. In some embodiments, the heterocycloalkyl is a 3-to 8-membered heterocycloalkenyl. In some embodiments, the heterocycloalkyl is a 3-to 7-membered heterocycloalkenyl.
• the heterocycloalkyl is a 3-to 6-membered heterocycloalkenyl. In some embodiments, the heterocycloalkyl is a 4-to 6-membered heterocycloalkenyl. In some embodiments, the heterocycloalkyl is a 5-to 6-membered heterocycloalkenyl.
• a heterocycloalkyl may be optionally substituted as described below, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like.
• the heterocycloalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -COOH, COOMe, -CF 3 , -OH, -OMe, -NH 2 , or -NO 2 .
• the heterocycloalkyl is optionally substituted with halogen, methyl, ethyl, -CN, -CF 3 , -OH, or -OMe. In some embodiments, the heterocycloalkyl is optionally substituted with halogen.
• Heteroaryl refers to a 5-to 14-membered ring system radical comprising one to thirteen carbon atoms, one to six heteroatoms selected from the group consisting of nitrogen, oxygen, phosphorous, and sulfur, and at least one aromatic ring.
• the heteroaryl comprises one to three heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur.
• the heteroaryl comprises one to three heteroatoms selected from the group consisting of nitrogen and oxygen.
• the heteroaryl comprises one to three nitrogens.
• the heteroaryl comprises one or two nitrogens.
• the heteroaryl comprises one nitrogen.
• the heteroaryl radical may be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may include fused (when fused with a cycloalkyl or heterocycloalkyl ring, the heteroaryl is bonded through an aromatic ring atom) or bridged ring systems; and the nitrogen, carbon, or sulfur atoms in the heteroaryl radical may be optionally oxidized; the nitrogen atom may be optionally quaternized.
• the heteroaryl is a 5-to 10-membered heteroaryl.
• the heteroaryl is a 5-to 6-membered heteroaryl.
• the heteroaryl is a 6-membered heteroaryl.
• the heteroaryl is a 5-membered heteroaryl.
• examples include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzodioxolyl, benzofuranyl, benzooxazolyl, benzothiazolyl, benzothiadiazolyl, benzo [b] [1, 4] dioxepinyl, 1, 4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothiophenyl) , benzotriazolyl, benzo [4, 6] imidazo [1, 2-a]pyridinyl, carbazolyl, cinnolinyl, dibenzofuranyl, dibenzofur
• a heteroaryl may be optionally substituted, for example, with halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like.
• the heteroaryl is optionally substituted with halogen, methyl, ethyl, -CN, -COOH, COOMe, -CF 3 , -OH, -OMe, -NH 2 , or -NO 2 .
• the heteroaryl is optionally substituted with halogen, methyl, ethyl, -CN, -CF 3 , -OH, or -OMe. In some embodiments, the heteroaryl is optionally substituted with halogen.
• an optionally substituted group may be un-substituted (e.g., -CH 2 CH 3 ) , fully substituted (e.g., -CF 2 CF 3 ) , mono-substituted (e.g., -CH 2 CH 2 F) or substituted at a level anywhere in-between fully substituted and mono-substituted (e.g., -CH 2 CHF 2 , -CH 2 CF 3 , -CF 2 CH 3 , -CFHCHF 2 , etc. ) .
• any substituents described should generally be understood as having a maximum molecular weight of about 1,000 daltons, and more typically, up to about 500 daltons.
• one or more when referring to an optional substituent means that the subject group is optionally substituted with one, two, three, or four substituents. In some embodiments, the subject group is optionally substituted with one, two, or three substituents. In some embodiments, the subject group is optionally substituted with one or two substituents. In some embodiments, the subject group is optionally substituted with one substituent. In some embodiments, the subject group is optionally substituted with two substituents.
• an “effective amount” or “therapeutically effective amount” refers to an amount of a compound administered to a mammalian subject, either as a single dose or as part of a series of doses, which is effective to produce a desired therapeutic effect.
• treat, ” “treating” or “treatment, ” as used herein, include alleviating, abating, or ameliorating at least one symptom of a disease or condition, preventing additional symptoms, inhibiting the disease or condition, e.g., arresting the development of the disease or condition, relieving the disease or condition, causing regression of the disease or condition, relieving a condition caused by the disease or condition, or stopping the symptoms of the disease or condition.
• a “disease or disorder associated with DGK” or, alternatively, “a DGK-mediated disease or disorder” means any disease or other deleterious condition in which DGK, or a mutant thereof, is known or suspected to play a role.
• a “disease or disorder associated with DGKalpha” or, alternatively, “a DGKalpha-mediated disease or disorder” means any disease or other deleterious condition in which DGKalpha, or a mutant thereof, is known or suspected to play a role.
• a “disease or disorder associated with DGKzeta” or, alternatively, “a DGKzeta-mediated disease or disorder” means any disease or other deleterious condition in which DGKzeta, or a mutant thereof, is known or suspected to play a role.
• Described herein are compounds, or a pharmaceutically acceptable salt thereof useful in the treatment of a disease or disorder associated with DGK, especially DGKalpha.
• Ring A is phenyl or 6-membered heteroaryl
• n 0-4;
• R 2 is hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, C 1 -C 6 heteroalkyl, cycloalkyl, or heterocycloalkyl;
• n 0-8;
• T is N or CR T ;
• p 0-4;
• each R a is independently C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, C 1 -C 6 heteroalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C 1 -C 6 alkylene (cycloalkyl) , C 1 -C 6 alkylene (heterocycloalkyl) , C 1 -C 6 alkylene (aryl) , or C 1 -C 6 alkylene (heteroaryl) , wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R;
• R a are taken together with the atom to which they are attached to form a heterocycloalkyl optionally substituted with one or more R;
• each R b is independently hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, C 1 -C 6 heteroalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C 1 -C 6 alkylene (cycloalkyl) , C 1 -C 6 alkylene (heterocycloalkyl) , C 1 -C 6 alkylene (aryl) , or C 1 -C 6 alkylene (heteroaryl) , wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R;
• R b are taken together with the atom to which they are attached to form a heterocycloalkyl optionally substituted with one or more R;
• R c and R d are each independently hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, C 1 -C 6 heteroalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C 1 -C 6 alkylene (cycloalkyl) , C 1 -C 6 alkylene (heterocycloalkyl) , C 1 -C 6 alkylene (aryl) , or C 1 -C 6 alkylene (heteroaryl) , wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R;
• R c and R d are taken together with the atom to which they are attached to form a heterocycloalkyl optionally substituted with one or more R;
• Ring A is phenyl or 6-membered heteroaryl
• n 0-4;
• R 2 is hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, C 1 -C 6 heteroalkyl, cycloalkyl, or heterocycloalkyl;
• n 0-8;
• T is N or CR T ;
• R T is hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, or C 1 -C 6 heteroalkyl;
• p 0-4;
• each R a is independently C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, C 1 -C 6 heteroalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C 1 -C 6 alkylene (cycloalkyl) , C 1 -C 6 alkylene (heterocycloalkyl) , C 1 -C 6 alkylene (aryl) , or C 1 -C 6 alkylene (heteroaryl) , wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R;
• R a are taken together with the atom to which they are attached to form a heterocycloalkyl optionally substituted with one or more R;
• each R b is independently hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, C 1 -C 6 heteroalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C 1 -C 6 alkylene (cycloalkyl) , C 1 -C 6 alkylene (heterocycloalkyl) , C 1 -C 6 alkylene (aryl) , or C 1 -C 6 alkylene (heteroaryl) , wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R;
• R b are taken together with the atom to which they are attached to form a heterocycloalkyl optionally substituted with one or more R;
• R c and R d are each independently hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, C 1 -C 6 heteroalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C 1 -C 6 alkylene (cycloalkyl) , C 1 -C 6 alkylene (heterocycloalkyl) , C 1 -C 6 alkylene (aryl) , or C 1 -C 6 alkylene (heteroaryl) , wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R;
• R c and R d are taken together with the atom to which they are attached to form a heterocycloalkyl optionally substituted with one or more R;
• Ring A is phenyl. In some embodiments of a compound of Formula (I) , Ring A is 6-membered heteroaryl. In some embodiments of a compound of Formula (I) , Ring A is pyridinyl.
• the compound is of Formula (Ia) :
• the compound is of Formula (Ib) :
• n’ is 0-3
• n’ is 0-3
• the compound is of Formula (Id) :
• n’ is 0-3
• the compound is of Formula (Ie) :
• n’ is 0-3
• the compound is of Formula (If) :
• each R 1a and R 1b are independently selected from R 1 .
• the compound is of Formula (Ig) :
• each R 1a and R 1b are independently selected from R 1 .
• n’ is 1 or 2; each R 1 is independently -CN, -O-heterocycloalkyl, -O-C 1 -C 6 alkyl, -O-C 1 -C 6 haloalkyl, -O-C 1 -C 6 hydroxylalkyl, or -O-C 1 -C 6 aminoalkyl; R 2 is C 1 -C 6 alkyl; T is CH; U is N or CH; p is 1 or 2; and each R 4 is independently halogen or C 1 -C 6 alkyl. In some embodiments of a compound of Formula (Ib) , p is 1.
• p is 2.
• R 4 is halogen such as F.
• R 4 is C 1 -C 6 alkyl.
• R 4 is C 1 -C 3 alkyl.
• R 4 is methyl.
• R 2 is C 1 -C 3 alkyl.
• R 2 is methyl.
• U is N. In some embodiments, U is CH.
• each R 1 is independently -CN, -O-heterocycloalkyl, -O-C 1 -C 6 haloalkyl, -O-C 1 -C 6 hydroxylalkyl, or -O-C 1 -C 6 aminoalkyl.
• each R 1 is independently -CN or -O-heterocycloalkyl.
• each R 1 is independently -CN or -O-C 1 -C 6 haloalkyl.
• each R 1 is independently -CN or -O-C 1 -C 6 hydroxylalkyl. In some embodiments of a compound of Formula (Ib) , each R 1 is independently -CN or -O-C 1 -C 3 hydroxylalkyl. In some embodiments of a compound of Formula (Ib) , each R 1 is independently -CN or -O-C 1 -C 6 aminoalkyl. In some embodiments of a compound of Formula (Ib) , each R 1 is independently -CN or -O-CH 2 CH 2 OH. In some embodiments of a compound of Formula (Ib) , at least one R 1 is CN. In some embodiments of a compound of Formula (Ib) , n’ is 1. In some embodiments of a compound of Formula (Ib) , n’ is 2.
• each R 1a and R 1b are independently -CN, -O-heterocycloalkyl, -O-C 1 -C 6 alkyl, -O-C 1 -C 6 haloalkyl, -O-C 1 -C 6 hydroxylalkyl, or -O-C 1 -C 6 aminoalkyl;
• R 2 is C 1 -C 6 alkyl;
• T is CH;
• U is N or CH;
• p is 1 or 2;
• each R 4 is independently halogen or C 1 -C 6 alkyl.
• p is 1.
• p is 2.
• R 4 is halogen such as F.
• R 4 is C 1 -C 6 alkyl.
• R 4 is C 1 -C 3 alkyl.
• R 4 is methyl.
• R 2 is C 1 -C 3 alkyl.
• R 2 is methyl.
• U is N.
• U is CH.
• each R 1a and R 1b are independently -CN, -O-heterocycloalkyl, -O-C 1 -C 6 haloalkyl, -O-C 1 -C 6 hydroxylalkyl, or -O-C 1 -C 6 aminoalkyl.
• each R 1a and R 1b are independently -CN or -O-heterocycloalkyl.
• each R 1a and R 1b are independently -CN or -O-C 1 -C 6 haloalkyl. In some embodiments of a compound of Formula (If) , each R 1a and R 1b are independently -CN or -O-C 1 -C 6 hydroxylalkyl. In some embodiments of a compound of Formula (If) , each R 1a and R 1b are independently -CN or -O-C 1 -C 6 aminoalkyl. In some embodiments of a compound of Formula (If) , R 1a is -O-C 1 -C 6 hydroxylalkyl, R 1b is CN.
• R 1a is -O-C 1 -C 3 hydroxylalkyl
• R 1b is CN.
• R 1a is -O-CH 2 CH 2 OH
• R 1b is CN.
• each R 1a and R 1b are independently -CN, -O-heterocycloalkyl, -O-C 1 -C 6 alkyl, -O-C 1 -C 6 haloalkyl, -O-C 1 -C 6 hydroxylalkyl, or -O-C 1 -C 6 aminoalkyl;
• R 2 is C 1 -C 6 alkyl;
• T is CH;
• U is N or CH;
• R 4 is halogen or C 1 -C 6 alkyl.
• R 4 is halogen such as F.
• R 4 is C 1 -C 6 alkyl. In some embodiments of a compound of Formula (Ig) , R 4 is C 1 -C 3 alkyl. In some embodiments of a compound of Formula (Ig) , R 4 is methyl. In some embodiments of a compound of Formula (Ig) , R 2 is C 1 -C 3 alkyl. In some embodiments of a compound of Formula (Ig) , R 2 is methyl. In some embodiments of a compound of Formula (Ig) , U is N. In some embodiments of a compound of Formula (Ig) , U is CH.
• each R 1a and R 1b are independently -CN, -O-heterocycloalkyl, -O-C 1 -C 6 haloalkyl, -O-C 1 -C 6 hydroxylalkyl, or -O-C 1 -C 6 aminoalkyl.
• each R 1a and R 1b are independently -CN or -O-heterocycloalkyl.
• each R 1a and R 1b are independently -CN or -O-C 1 -C 6 haloalkyl.
• each R 1a and R 1b are independently -CN or -O-C 1 -C 6 hydroxylalkyl. In some embodiments of a compound of Formula (Ig) , each R 1a and R 1b are independently -CN or -O-C 1 -C 6 aminoalkyl. In some embodiments of a compound of Formula (Ig) , R 1a is -O-C 1 -C 6 hydroxylalkyl, and R 1b is CN. In some embodiments of a compound of Formula (Ig) , R 1a is -O-C 1 -C 3 hydroxylalkyl, and R 1b is CN. In some embodiments of a compound of Formula (Ig) , R 1a is -O-CH 2 CH 2 OH, and R 1b is CN.
• R 1a is halogen, -CN, -OH, -OR a , -NR c R d , C 1 -C 6 alkyl, or C 1 -C 6 haloalkyl.
• R 1a is halogen, -CN, C 1 -C 6 alkyl, or C 1 -C 6 haloalkyl.
• R 1a is halogen or -CN.
• R 1a is halogen. In some embodiments of a compound of Formula (If) or (Ig) , R 1a is fluoro or chloro. In some embodiments of a compound of Formula (If) or (Ig) , R 1a is -CN. In some embodiments of a compound of Formula (If) or (Ig) , R 1a is independently halogen, -CN, -OR a , or -NR c R d . In some embodiments of a compound of Formula (If) or (Ig) , R 1a is -CN or -OR a .
• R 1a is -CN, -O-heterocycloalkyl, -O-C 1 -C 6 alkyl, -O-C 1 -C 6 haloalkyl, -O-C 1 -C 6 hydroxylalkyl, or -O-C 1 -C 6 aminoalkyl.
• R 1a is -CN, -O-heterocycloalkyl, -O-C 1 -C 3 alkyl, -O-C 1 -C 3 haloalkyl, -O-C 1 -C 3 hydroxylalkyl, or -O-C 1 -C 3 aminoalkyl.
• R 1a is independently -CN or -NR c R d .
• -OR a is -O-heterocycloalkyl, -O-C 1 -C 6 alkyl, -O-C 1 -C 6 haloalkyl, -O-C 1 -C 6 hydroxylalkyl, or -O-C 1 -C 6 aminoalkyl.
• -OR a is -O-heterocycloalkyl, wherein the heterocycloalkyl is a 5 or 6 membered ring.
• -OR a is In some embodiments of a compound of Formula (If) or (Ig) , -OR a is -O-C 1 -C 6 alkyl. In some embodiments of a compound of Formula (If) or (Ig) , -OR a is -O-C 1 -C 6 haloalkyl. In some embodiments of a compound of Formula (If) or (Ig) , -OR a is -O-C 1 -C 6 hydroxylalkyl. In some embodiments of a compound of Formula (If) or (Ig) , -OR a is -O-C 1 -C 6 aminoalkyl.
• R 1b is halogen, -CN, -OH, -OR a , -NR c R d , C 1 -C 6 alkyl, or C 1 -C 6 haloalkyl.
• R 1b is halogen, -CN, C 1 -C 6 alkyl, or C 1 -C 6 haloalkyl.
• R 1b is halogen or -CN.
• R 1b is halogen. In some embodiments of a compound of Formula (If) or (Ig) , R 1b is fluoro or chloro. In some embodiments of a compound of Formula (If) or (Ig) , R 1b is -CN. In some embodiments of a compound of Formula (If) or (Ig) , R 1b is independently halogen, -CN, -OR a , or -NR c R d . In some embodiments of a compound of Formula (If) or (Ig) , R 1b is -CN or -OR a .
• R 1b is -CN, -O-heterocycloalkyl, -O-C 1 -C 6 alkyl, -O-C 1 -C 6 haloalkyl, -O-C 1 -C 6 hydroxylalkyl, or -O-C 1 -C 6 aminoalkyl.
• R 1b is -CN, -O-heterocycloalkyl, -O-C 1 -C 3 alkyl, -O-C 1 -C 3 haloalkyl, -O-C 1 -C 3 hydroxylalkyl, or -O-C 1 -C 3 aminoalkyl.
• R 1b is independently -CN or -NR c R d .
• -OR a is -O-heterocycloalkyl, -O-C 1 -C 6 alkyl, -O-C 1 -C 6 haloalkyl, -O-C 1 -C 6 hydroxylalkyl, or -O-C 1 -C 6 aminoalkyl.
• -OR a is -O-heterocycloalkyl, wherein the heterocycloalkyl is a 5 or 6 membered ring.
• -OR a is In some embodiments of a compound of Formula (If) or (Ig) , -OR a is -O-C 1 -C 6 alkyl. In some embodiments of a compound of Formula (If) or (Ig) , -OR a is -O-C 1 -C 6 haloalkyl. In some embodiments of a compound of Formula (If) or (Ig) , -OR a is -O-C 1 -C 6 hydroxylalkyl. In some embodiments of a compound of Formula (If) or (Ig) , -OR a is -O-C 1 -C 6 aminoalkyl.
• n is 0, 1, 2, 3, or 4. In some embodiments of a compound of Formula (I) or (Ia) , wherein n is 0-2. In some embodiments of a compound of Formula (I) or (Ia) , n is 0 or 1. In some embodiments of a compound of Formula (I) or (Ia) , n is 2. In some embodiments of a compound of Formula (I) or (Ia) , n is 1. In some embodiments of a compound of Formula (I) or (Ia) , n is 0.
• n’ is 0, 1, 2, or 3. In some embodiments of a compound of Formula (Ib) - (Ie) , n’ is 0-2. In some embodiments of a compound of Formula (Ib) - (Ie) , n’ is 0 or 1. In some embodiments of a compound of Formula (Ib) - (Ie) , n’ is 2. In some embodiments of a compound of Formula (Ib) - (Ie) , n’ is 1. In some embodiments of a compound of Formula (Ib) - (Ie) , n’ is 0.
• each R 1 is independently halogen, -CN, -OH, -OR a , -NR c R d , C 1 -C 6 alkyl, or C 1 -C 6 haloalkyl.
• each R 1 is independently halogen, -CN, C 1 -C 6 alkyl, or C 1 -C 6 haloalkyl.
• each R 1 is independently halogen or -CN.
• each R 1 is independently halogen. In some embodiments of a compound of Formula (I) or (Ia) - (Ig) , each R 1 is fluoro or chloro. In some embodiments of a compound of Formula (I) or (Ia) - (Ig) , each R 1 is -CN. In some embodiments of a compound of Formula (I) or (Ia) -(Ig) , each R 1 is independently halogen, -CN, -OR a , or -NR c R d .
• each R 1 is independently -CN or -OR a . In some embodiments of a compound of Formula (I) or (Ia) - (Ig) , each R 1 is independently -CN, -O-heterocycloalkyl, -O-C 1 -C 6 alkyl, -O-C 1 -C 6 haloalkyl, -O-C 1 -C 6 hydroxylalkyl, or -O-C 1 -C 6 aminoalkyl.
• each R 1 is independently -CN, -O-heterocycloalkyl, -O-C 1 -C 3 alkyl, -O-C 1 -C 3 haloalkyl, -O-C 1 -C 3 hydroxylalkyl, or -O-C 1 -C 3 aminoalkyl.
• each R 1 is independently -CN or -NR c R d .
• -OR a is -O-heterocycloalkyl, -O-C 1 -C 6 alkyl, -O-C 1 -C 6 haloalkyl, -O-C 1 -C 6 hydroxylalkyl, or -O-C 1 -C 6 aminoalkyl.
• -OR a is -O-heterocycloalkyl, wherein the heterocycloalkyl is a 5 or 6 membered ring.
• -OR a is In some embodiments of a compound of Formula (I) or (Ia) - (Ig) , -OR a is -O-C 1 -C 6 alkyl. In some embodiments of a compound of Formula (I) or (Ia) - (Ig) , -OR a is -O-C 1 -C 6 haloalkyl. In some embodiments of a compound of Formula (I) or (Ia) - (Ig) , -OR a is -O-C 1 -C 6 hydroxylalkyl.
• -OR a is -O-C 1 -C 6 aminoalkyl.
• each R 1 is independently -CN, -O-heterocycloalkyl, -O-C 1 -C 6 haloalkyl, -O-C 1 -C 6 hydroxylalkyl, or -O-C 1 -C 6 aminoalkyl.
• each R 1 is independently -CN or -O-heterocycloalkyl.
• each R 1 is independently -CN or -O-C 1 -C 6 haloalkyl.
• each R 1 is independently -CN or -O-C 1 -C 6 hydroxylalkyl. In some embodiments, each R 1 is independently -CN or -O-C 1 -C 3 hydroxylalkyl. In some embodiments, each R 1 is independently -CN or -O-CH 2 CH 2 OH. In some embodiments, each R 1 is independently -CN or -O-C 1 -C 6 aminoalkyl. In some embodiments, at least one R 1 is -CN.
• R 2 is hydrogen or C 1 -C 6 alkyl. In some embodiments of a compound of Formula (I) or (Ia) - (Ig) , R 2 is C 1 -C 6 alkyl. In some embodiments of a compound of Formula (I) or (Ia) - (Ig) , R 2 is C 1 -C 3 alkyl. In some embodiments of a compound of Formula (I) or (Ia) - (Ig) , R 2 is methyl.
• U is N. In some embodiments of a compound of Formula (I) or (Ia) - (Ig) , U is CR U .
• R U is hydrogen, halogen, -OH, -OR a , -NR c R d , C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, C 1 -C 6 heteroalkyl, cycloalkyl, or heterocycloalkyl.
• R U is hydrogen, halogen, C 1 -C 6 alkyl, or C 1 -C 6 haloalkyl.
• R U is hydrogen.
• a compound of Formula (I) is In some embodiments of a compound of Formula (I) , is In some embodiments of a compound of Formula (I) , is In some embodiments of a compound of Formula (I) , is In some embodiments of a compound of Formula (I) , is in some embodiments of a compound of Formula (I) , is in some embodiments of a compound of Formula (I) , is in some embodiments of a compound of Formula (I) , is
• each R 3 is independently halogen, -CN, -OH, -OR a , -NR c R d , C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, C 1 -C 6 heteroalkyl, cycloalkyl, or heterocycloalkyl.
• each R 3 is independently C 1 -C 6 alkyl or C 1 -C 6 haloalkyl.
• each R 3 is independently C 1 -C 6 alkyl.
• two R 3 on the same or different carbons are taken together to form a cycloalkyl or heterocycloalkyl, each optionally substituted with one or more R.
• two R 3 on different carbons are taken together to form a cycloalkyl optionally substituted with one or more R.
• m is 0-4. In some embodiments of a compound of Formula (I) or (Ia) - (Ie) , m is 0-3. In some embodiments of a compound of Formula (I) or (Ia) - (Ie) , m is 0-2. In some embodiments of a compound of Formula (I) or (Ia) - (Ie) , m is 0. In some embodiments of a compound of Formula (I) or (Ia) - (Ie) , m is 1. In some embodiments of a compound of Formula (I) or (Ia) - (Ie) , m is 2.
• m is 3. In some embodiments of a compound of Formula (I) or (Ia) - (Ie) , m is 4. In some embodiments of a compound of Formula (I) or (Ia) - (Ie) , m is 3. In some embodiments of a compound of Formula (I) or (Ia) - (Ie) , m is 5-8.
• T is N. In some embodiments of a compound of Formula (I) or (Ia) - (Ig) , T is CR T .
• R T is hydrogen or C 1 -C 6 alkyl. In some embodiments of a compound of Formula (I) or (Ia) - (Ig) , R T is hydrogen.
• each R 4 is independently halogen, -CN, -OH, -OR a , -NR c R d , C 1 -C 6 alkyl, or C 1 -C 6 haloalkyl. In some embodiments of a compound of Formula (I) or (Ia) -(Ig) , each R 4 is independently halogen, C 1 -C 6 alkyl, or C 1 -C 6 haloalkyl. In some embodiments of a compound of Formula (I) or (Ia) - (Ig) , each R 4 is independently halogen or C 1 -C 6 alkyl.
• each R 4 is independently C 1 -C 6 alkyl. In some embodiments of a compound of Formula (I) or (Ia) - (Ig) , each R 4 is methyl. In some embodiments of a compound of Formula (I) or (Ia) - (Ig) , R 4 is F.
• p is 0-2. In some embodiments of a compound of Formula (I) or (Ia) - (If) , p is 1 or 2. In some embodiments of a compound of Formula (I) or (Ia) - (If) , p is 0. In some embodiments of a compound of Formula (I) or (Ia) - (If) , p is 1. In some embodiments of a compound of Formula (I) or (Ia) - (If) , p is 2.
• Ring A is phenyl or 6-membered heteroaryl
• n 0-4;
• R 2 is hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, C 1 -C 6 heteroalkyl, cycloalkyl, or heterocycloalkyl;
• Ring B is a bicyclic ring
• n 0-8;
• p 0-4;
• each R a is independently C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, C 1 -C 6 heteroalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C 1 -C 6 alkylene (cycloalkyl) , C 1 -C 6 alkylene (heterocycloalkyl) , C 1 -C 6 alkylene (aryl) , or C 1 -C 6 alkylene (heteroaryl) , wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R;
• R a are taken together with the atom to which they are attached to form a heterocycloalkyl optionally substituted with one or more R;
• each R b is independently hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, C 1 -C 6 heteroalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C 1 -C 6 alkylene (cycloalkyl) , C 1 -C 6 alkylene (heterocycloalkyl) , C 1 -C 6 alkylene (aryl) , or C 1 -C 6 alkylene (heteroaryl) , wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R;
• R b are taken together with the atom to which they are attached to form a heterocycloalkyl optionally substituted with one or more R;
• R c and R d are each independently hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, C 1 -C 6 heteroalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C 1 -C 6 alkylene (cycloalkyl) , C 1 -C 6 alkylene (heterocycloalkyl) , C 1 -C 6 alkylene (aryl) , or C 1 -C 6 alkylene (heteroaryl) , wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R;
• R c and R d are taken together with the atom to which they are attached to form a heterocycloalkyl optionally substituted with one or more R;
• Ring A is phenyl. In some embodiments of a compound of Formula (II) , Ring A is 6-membered heteroaryl. In some embodiments of a compound of Formula (II) , Ring A is pyridinyl.
• the compound is of Formula (IIa) :
• the compound is of Formula (IIb) :
• n’ is 0-3
• the compound is of Formula (IIc) :
• n’ is 0-3
• the compound is of Formula (IId) :
• n’ is 0-3
• the compound is of Formula (IIe) :
• n’ is 0-3
• the compound is of Formula (IIf) :
• each R 1a and R 1b are independently selected from R 1 .
• n is 0, 1, 2, 3, or 4. In some embodiments of a compound of Formula (II) or (IIa) , n is 0-2. In some embodiments of a compound of Formula (II) or (IIa) , n is 0 or 1. In some embodiments of a compound of Formula (II) or (IIa) , n is 2. In some embodiments of a compound of Formula (II) or (IIa) , n is 1. In some embodiments of a compound of Formula (II) or (IIa) , n is 0.
• n’ is 0-2. In some embodiments of a compound of Formula (IIb) - (IIe) , n’ is 0 or 1. In some embodiments of a compound of Formula (IIb) - (IIe) , n’ is 2. In some embodiments of a compound of Formula (IIb) - (IIe) , n’ is 1. In some embodiments of a compound of Formula (IIb) - (IIe) , n’ is 0.
• each R 1 is independently halogen, -CN, -OH, -OR a , -NR c R d , C 1 -C 6 alkyl, or C 1 -C 6 haloalkyl.
• each R 1 is independently halogen, -CN, C 1 -C 6 alkyl, or C 1 -C 6 haloalkyl.
• each R 1 is independently halogen or -CN.
• each R 1 is independently halogen. In some embodiments of a compound of Formula (II) or (IIa) - (IIf) , each R 1 is fluoro or chloro. In some embodiments of a compound of Formula (II) or (IIa) - (IIf) , each R 1 is -CN. In some embodiments of a compound of Formula (II) or (IIa) - (IIf) , each R 1 is independently halogen, -CN, -OR a , or -NR c R d .
• each R 1 is independently -CN or -OR a . In some embodiments of a compound of Formula (II) or (IIa) - (IIf) , each R 1 is independently -CN or -NR c R d .
• -OR a is -O-heterocycloalkyl, -O-C 1 -C 6 alkyl, -O-C 1 -C 6 haloalkyl, -O-C 1 -C 6 hydroxylalkyl, -O-C 1 -C 6 aminoalkyl.
• -OR a is -O-heterocycloalkyl, wherein the heterocycloalkyl is a 5 or 6 membered ring.
• -OR a is In some embodiments of a compound of Formula (II) or (IIa) - (IIf) , -OR a is -O-C 1 -C 6 alkyl. In some embodiments of a compound of Formula (II) or (IIa) - (IIf) , -OR a is -O-C 1 -C 6 haloalkyl. In some embodiments of a compound of Formula (II) or (IIa) - (IIf) , -OR a is -O-C 1 -C 6 hydroxylalkyl.
• -OR a is -O-C 1 -C 6 aminoalkyl.
• each R 1 is independently -CN, -O-heterocycloalkyl, -O-C 1 -C 6 haloalkyl, -O-C 1 -C 6 hydroxylalkyl, or -O-C 1 -C 6 aminoalkyl.
• each R 1 is independently -CN or -O-heterocycloalkyl.
• each R 1 is independently -CN or -O-C 1 -C 6 haloalkyl.
• each R 1 is independently -CN or -O-C 1 -C 6 hydroxylalkyl. In some embodiments, each R 1 is independently -CN or -O-C 1 -C 6 aminoalkyl. In some embodiments, at least one R 1 is -CN.
• R 2 is hydrogen or C 1 -C 6 alkyl. In some embodiments of a compound of Formula (II) or (IIa) - (IIf) , R 2 is C 1 -C 6 alkyl.
• U is N. In some embodiments of a compound of Formula (II) or (IIa) - (IIf) , U is CR U .
• R U is hydrogen or -CN.
• R U is -CN.
• a compound of Formula (II) is In some embodiments of a compound of Formula (II) , is , In some embodiments of a compound of Formula (II) , is In some embodiments of a compound of Formula (II) , is In some embodiments of a compound of Formula (II) , is in some embodiments of a compound of Formula (II) , is in some embodiments of a compound of Formula (II) , is
• Ring B is a bicyclic heterocycloalkyl. In some embodiments of a compound of Formula (II) or (IIa) - (IIf) , Ring B is a bicyclic 6-to 10-membered heterocycloalkyl. In some embodiments of a compound of Formula (II) or (IIa) - (IIf) , Ring B is a bicyclic 6-to 10-membered heterocycloalkyl comprising 1 to 3 heteroatoms selected from the group consisting of N, O, and S.
• Ring B is a bicyclic 6-to 10-membered heterocycloalkyl comprising 1 to 3 heteroatoms selected from the group consisting of N and O.
• Ring B is a bridged bicyclic ring.
• Ring B is 3,8-diazabicyclo [3.2.1] octane or 2, 5-diazabicyclo [2.2.2] octane.
• Ring B is 3,8-diazabicyclo [3.2.1] octane or 2, 5-diazabicyclo [2.2.2] octane.
• each R 3 is independently halogen, -CN, -OH, -OR a , -NR c R d , C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, C 1 -C 6 heteroalkyl, cycloalkyl, or heterocycloalkyl.
• each R 3 is independently C 1 -C 6 alkyl or C 1 -C 6 haloalkyl.
• each R 3 is independently C 1 -C 6 alkyl. In some embodiments of a compound of Formula (II) or (IIa) - (IIf) , each R 3 is independently methyl or ethyl.
• m is 0-4. In some embodiments of a compound of Formula (II) or (IIa) - (IIf) , m is 0-3. In some embodiments of a compound of Formula (II) or (IIa) - (IIf) , m is 0-2. In some embodiments of a compound of Formula (II) or (IIa) - (IIf) , m is 2. In some embodiments of a compound of Formula (II) or (IIa) - (IIf) , m is 1.
• m is 2. In some embodiments of a compound of Formula (II) or (IIa) - (IIf) , m is 3. In some embodiments of a compound of Formula (II) or (IIa) - (IIf) , m is 4. In some embodiments of a compound of Formula (II) or (IIa) - (IIf) , m is 5-8
• each R 4 is independently halogen, -CN, -OH, -OR a , -NR c R d , C 1 -C 6 alkyl, or C 1 -C 6 haloalkyl. In some embodiments of a compound of Formula (II) or (IIa) - (IIf) , each R 4 is independently halogen, C 1 -C 6 alkyl, or C 1 -C 6 haloalkyl.
• each R 4 is independently halogen or C 1 -C 6 alkyl. In some embodiments of a compound of Formula (II) or (IIa) - (IIf) , each R 4 is independently C 1 -C 6 alkyl. In some embodiments of a compound of Formula (II) or (IIa) - (IIf) , each R 4 is methyl. In some embodiments of a compound of Formula (II) or (IIa) - (IIf) , R 4 is F.
• p is 0-2. In some embodiments of a compound of Formula (II) or (IIa) - (IIf) , p is 1 or 2. In some embodiments of a compound of Formula (II) or (IIa) - (IIf) , p is 2. In some embodiments of a compound of Formula (II) or (IIa) - (IIf) , p is 1. In some embodiments of a compound of Formula (II) or (IIa) - (IIf) , p is 0.
• each R a is independently C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, C 1 -C 6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C 1 -C 6 alkylene (cycloalkyl) , C 1 -C 6 alkylene (heterocycloalkyl) , C 1 -C 6 alkylene (aryl) , or C 1 -C 6 alkylene (heteroaryl) ; wherein each alkyl, alkylene, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R.
• each R a is independently C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, or cycloalkyl, heterocycloalkyl; wherein each alkyl, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one or more R.
• each R a is independently C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, C 1 -C 6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C 1 -C 6 alkylene (cycloalkyl) , C 1 -C 6 alkylene (heterocycloalkyl) , C 1 -C 6 alkylene (aryl) , or C 1 -C 6 alkylene (heteroaryl) .
• each R a is independently C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, or cycloalkyl, heterocycloalkyl. In some embodiments of a compound disclosed herein, each R a is independently C 1 -C 6 alkyl or C 1 -C 6 haloalkyl. In some embodiments of a compound disclosed herein, each R a is independently C 1 -C 6 alkyl.
• each R b is independently hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, C 1 -C 6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C 1 -C 6 alkylene (cycloalkyl) , C 1 -C 6 alkylene (heterocycloalkyl) , C 1 -C 6 alkylene (aryl) , or C 1 -C 6 alkylene (heteroaryl) ; wherein each alkyl, alkylene, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R.
• each R b is independently hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, or cycloalkyl, heterocycloalkyl; wherein each alkyl, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one or more R.
• each R b is independently hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, C 1 -C 6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C 1 -C 6 alkylene (cycloalkyl) , C 1 -C 6 alkylene (heterocycloalkyl) , C 1 -C 6 alkylene (aryl) , or C 1 -C 6 alkylene (heteroaryl) .
• each R b is independently hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, or cycloalkyl, heterocycloalkyl. In some embodiments of a compound disclosed herein, each R b is independently hydrogen, C 1 -C 6 alkyl or C 1 -C 6 haloalkyl. In some embodiments of a compound disclosed herein, each R b is independently hydrogen or C 1 -C 6 alkyl. In some embodiments of a compound disclosed herein, each R b is hydrogen. In some embodiments of a compound disclosed herein, each R b is independently C 1 -C 6 alkyl.
• each R c and R d are independently hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, C 1 -C 6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C 1 -C 6 alkylene (cycloalkyl) , C 1 -C 6 alkylene (heterocycloalkyl) , C 1 -C 6 alkylene (aryl) , or C 1 -C 6 alkylene (heteroaryl) ; wherein each alkyl, alkylene, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R.
• each R c and R d are independently hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, or cycloalkyl, heterocycloalkyl; wherein each alkyl, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one or more R.
• each R c and R d are independently hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, C 1 -C 6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C 1 -C 6 alkylene (cycloalkyl) , C 1 -C 6 alkylene (heterocycloalkyl) , C 1 -C 6 alkylene (aryl) , or C 1 -C 6 alkylene (heteroaryl) .
• each R c and R d are independently hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, or cycloalkyl, heterocycloalkyl. In some embodiments of a compound disclosed herein, each R c and R d are independently hydrogen, C 1 -C 6 alkyl or C 1 -C 6 haloalkyl. In some embodiments of a compound disclosed herein, each R c and R d are independently hydrogen or C 1 -C 6 alkyl. In some embodiments of a compound disclosed herein, each R c and R d are hydrogen. In some embodiments of a compound disclosed herein, each R c and R d are independently C 1 -C 6 alkyl.
• R c and R d are taken together with the atom to which they are attached to form a heterocycloalkyl optionally substituted with one or more R.
• each R is independently halogen, -CN, -OH, -NH 2 , -NHCH 3 , -N (CH 3 ) 2 , C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, C 1 -C 6 heteroalkyl, or C 3 -C 6 cycloalkyl; or two R on the same atom form an oxo.
• each R is independently halogen, -CN, -OH, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, or C 1 -C 6 haloalkyl; or two R on the same atom form an oxo. In some embodiments of a compound disclosed herein, each R is independently halogen, -CN, -OH, or C 1 -C 6 alkyl; or two R on the same atom form an oxo. In some embodiments of a compound disclosed herein, each R is independently halogen, -OH, or C 1 -C 6 alkyl. In some embodiments of a compound disclosed herein, each R is independently halogen or C 1 -C 6 alkyl. In some embodiments of a compound disclosed herein, each R is independently halogen.
• one or more of R, R 1 , R 2 , R 3 , R 4 , R U , R T , R a , R b , R c , and R d groups comprise deuterium at a percentage higher than the natural abundance of deuterium.
• one or more 1 H are replaced with one or more deuteriums in one or more of the following groups R, R 1 , R 2 , R 3 , R 4 , R U , R T , R a , R b , R c , and R d .
• the abundance of deuterium in each of R, R 1 , R 2 , R 3 , R 4 , R U , R T , R a , R b , R c , and R d is independently at least 1%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or 100%by molar.
• one or more 1 H of Ring A or Ring B are replaced with one or more deuteriums.
• the compound disclosed herein, or a pharmaceutically acceptable salt thereof is one of the compounds in Table 1.
• the compound disclosed herein, or a pharmaceutically acceptable salt thereof is one of the compounds in Table 2.
• the compounds described herein exist as geometric isomers. In some embodiments, the compounds described herein possess one or more double bonds. The compounds presented herein include all cis, trans, syn, anti,
• Z) isomers as well as the corresponding mixtures thereof. In some situations, the compounds described herein possess one or more chiral centers and each center exists in the R configuration, or S configuration. The compounds described herein include all diastereomeric, enantiomeric, and epimeric forms as well as the corresponding mixtures thereof.
• mixtures of enantiomers and/or diastereoisomers, resulting from a single preparative step, combination, or interconversion are useful for the applications described herein.
• the compounds described herein are prepared as their individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereoisomeric compounds, separating the diastereomers and recovering the optically pure enantiomers.
• dissociable complexes are preferred.
• the diastereomers have distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.
• the diastereomers are separated by chiral chromatography, or preferably, by separation/resolution techniques based upon differences in solubility.
• the optically pure enantiomer is then recovered, along with the resolving agent, by any practical means that would not result in racemization.
• compounds described herein may exhibit their natural isotopic abundance, or one or more of the atoms may be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominantly found in nature. All isotopic variations of the compounds of the present disclosure, whether radioactive or not, are encompassed within the scope of the present disclosure.
• hydrogen has three naturally occurring isotopes, denoted 1 H (protium) , 2 H (deuterium) , and 3 H (tritium) .
• Protium is the most abundant isotope of hydrogen in nature. Enriching for deuterium may afford some therapeutic advantages, such as increased in vivo half-life and/or exposure, or may provide a compound useful for investigating in vivo routes of drug elimination and metabolism.
• the compounds described herein may be artificially enriched in one or more particular isotopes.
• the compounds described herein may be artificially enriched in one or more isotopes that are not predominantly found in nature.
• the compounds described herein may be artificially enriched in one or more isotopes selected from deuterium ( 2 H) , tritium ( 3 H) , iodine-125 ( 125 I) or carbon-14 ( 14 C) .
• the compounds described herein are artificially enriched in one or more isotopes selected from 2 H, 11 C, 13 C, 14 C, 15 C, 12 N, 13 N, 15 N, 16 N, 16 O, 17 O, 14 F, 15 F, 16 F, 17 F, 18 F, 33 S, 34 S, 35 S, 36 S, 35 Cl, 37 Cl, 79 Br, 81 Br, 131 I, and 125 I.
• the abundance of the enriched isotopes is independently at least 1%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or 100%by molar.
• the compound is deuterated in at least one position.
• the compounds disclosed herein have some or all of the 1 H atoms replaced with 2 H atoms.
• deuterium substituted compounds may be synthesized using various methods such as described in: Dean, Dennis C.; Editor. Recent Advances in the Synthesis and Applications of Radiolabeled Compounds for Drug Discovery and Development. [In: Curr., Pharm. Des., 2000; 6 (10) ] 2000, 110 pp; George W.; Varma, Rajender S. The Synthesis of Radiolabeled Compounds via Organometallic Intermediates, Tetrahedron, 1989, 45 (21) , 6601-21; and Evans, E.
• the compounds described herein exist as their pharmaceutically acceptable salts.
• the methods disclosed herein include methods of treating diseases by administering such pharmaceutically acceptable salts.
• the methods disclosed herein include methods of treating diseases by administering such pharmaceutically acceptable salts as pharmaceutical compositions.
• the compounds described herein possess acidic or basic groups and therefore react with any of a number of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt.
• these salts are prepared in situ during the final isolation and purification of the compounds disclosed herein , or by separately reacting a purified compound in its free form with a suitable acid or base, and isolating the salt thus formed.
• Examples of pharmaceutically acceptable salts include those salts prepared by reaction of the compounds described herein with a mineral, organic acid or inorganic base, such salts including, acetate, acrylate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, bisulfite, bromide, butyrate, butyn-1, 4-dioate, camphorate, camphorsulfonate, caproate, caprylate, chlorobenzoate, chloride, citrate, cyclopentanepropionate, decanoate, digluconate, dihydrogenphosphate, dinitrobenzoate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptanoate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hexyne-1, 6-dioate, hydroxybenzoate,
• the compounds described herein can be prepared as pharmaceutically acceptable salts formed by reacting the free base form of the compound with a pharmaceutically acceptable inorganic or organic acid, including, but not limited to, inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid metaphosphoric acid, and the like; and organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, p-toluenesulfonic acid, tartaric acid, trifluoroacetic acid, citric acid, benzoic acid, 3- (4-hydroxybenzoyl) benzoic acid, cinnamic acid, mandelic acid, arylsulfonic acid, methanesulfonic acid, ethanesulfonic acid, 1, 2-ethanedis
• those compounds described herein which comprise a free acid group react with a suitable base, such as the hydroxide, carbonate, bicarbonate, sulfate, of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary, tertiary, or quaternary amine.
• a suitable base such as the hydroxide, carbonate, bicarbonate, sulfate, of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary, tertiary, or quaternary amine.
• Representative salts include the alkali or alkaline earth salts, like lithium, sodium, potassium, calcium, and magnesium, and aluminum salts and the like.
• bases include sodium hydroxide, potassium hydroxide, choline hydroxide, sodium carbonate, N + (C 1-4 alkyl) 4 , and the like.
• Organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine and the like. It should be understood that the compounds described herein also include the quaternization of any basic nitrogen-containing groups they contain. In some embodiments, water or oil-soluble or dispersible products are obtained by such quaternization.
• Tautomers are compounds that are interconvertible by migration of a hydrogen atom, accompanied by a switch of a single bond and adjacent double bond. In bonding arrangements where tautomerization is possible, a chemical equilibrium of the tautomers will exist. All tautomeric forms of the compounds disclosed herein are contemplated. The exact ratio of the tautomers depends on several factors, including temperature, solvent, and pH.
• the disease is cancer.
• the disease is cancer or a viral infection.
• the cancer is a solid tumor. In some embodiments, the cancer is a hematological cancer. In some embodiments, the cancer is breast cancer, cervical cancer, colon cancer, head and neck cancer, leukemia, liver cancer, lung cancer, lymphoma, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, thyroid cancer, or urinary track cancer.
• the viral infection is an HIV infection, an hepatitis B virus infection, an hepatitis C virus infection, a human papilloma virus infection, a cytomegalovirus infection, herpes simplex virus infection, Epstein-Barr virus infection, or a varicella zoster virus infection.
• Disclosed herein is a method of inhibiting the activity of at least one of diacylglycerol kinase comprising administering to the subject a therapeutically affective amount of a compound, or a pharmaceutically acceptable salt thereof, disclosed herein.
• the diacylglycerol kinase is diacylglycerol kinase alpha (DGKalpha) .
• the diacylglycerol kinase is diacylglycerol kinase zeta (DGKzeta) .
• Disclosed herein is a method of modulating the activity of at least one of diacylglycerol kinase selected from diacylglycerol kinase alpha (DGKalpha) and diacylglycerol kinase zeta (DGKzeta) , in a subject in need thereof, the method comprising administering to the subject a compound, or a pharmaceutically acceptable salt thereof, disclosed herein.
• DGKalpha diacylglycerol kinase alpha
• DGKzeta diacylglycerol kinase zeta
• the subject has a disease described herein.
• the subject has cancer.
• compositions containing the compound (s) described herein are administered for therapeutic treatments.
• the compositions are administered to a patient already suffering from a disease or condition, in an amount sufficient to cure or at least partially arrest at least one of the symptoms of the disease or condition. Amounts effective for this use depend on the severity and course of the disease or condition, previous therapy, the patient’s health status, weight, and response to the drugs, and the judgment of the treating physician. Therapeutically effective amounts are optionally determined by methods including, but not limited to, a dose escalation and/or dose ranging clinical trial.
• the administration of the compounds are administered chronically, that is, for an extended period of time, including throughout the duration of the patient’s life in order to ameliorate or otherwise control or limit the symptoms of the patient’s disease or condition.
• a maintenance dose is administered if necessary. Subsequently, in specific embodiments, the dosage, or the frequency of administration, or both, is reduced, as a function of the symptoms.
• the amount of a given agent that corresponds to such an amount varies depending upon factors such as the particular compound, disease condition and its severity, the identity (e.g., weight, sex) of the subject or host in need of treatment, but nevertheless is determined according to the particular circumstances surrounding the case, including, e.g., the specific agent being administered, the route of administration, the condition being treated, and the subject or host being treated.
• doses employed for adult human treatment are typically in the range of 0.01 mg-5000 mg per day.
• the daily dosages appropriate for the compound described herein, or a pharmaceutically acceptable salt thereof are from about 0.01 to about 50 mg/kg per body weight.
• the daily and unit dosages are altered depending on a number of variables including, but not limited to, the activity of the compound used, the disease or condition to be treated, the mode of administration, the requirements of the individual subject, the severity of the disease or condition being treated, and the judgment of the practitioner.
• Suitable routes of administration include, but are not limited to, oral, intravenous, rectal, aerosol, parenteral, ophthalmic, pulmonary, transmucosal, transdermal, vaginal, otic, nasal, and topical administration.
• parenteral delivery includes intramuscular, subcutaneous, intravenous, intramedullary injections, as well as intrathecal, direct intraventricular, intraperitoneal, intralymphatic, and intranasal injections.
• a compound as described herein is administered in a local rather than systemic manner, for example, via injection of the compound directly into an organ, often in a depot preparation or sustained release formulation.
• long acting formulations are administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
• the drug is delivered in a targeted drug delivery system, for example, in a liposome coated with organ specific antibody.
• the liposomes are targeted to and taken up selectively by the organ.
• the compound as described herein is provided in the form of a rapid release formulation, in the form of an extended release formulation, or in the form of an intermediate release formulation.
• the compounds described herein are administered to a subject in need thereof, either alone or in combination with pharmaceutically acceptable carriers, excipients, or diluents, in a pharmaceutical composition, according to standard pharmaceutical practice. In some embodiments, the compounds described herein are administered to animals.
• compositions comprising a compound described herein, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.
• Pharmaceutical compositions are formulated in a conventional manner using one or more pharmaceutically acceptable excipients that facilitate processing of the active compounds into preparations that can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.
• a summary of pharmaceutical compositions described herein can be found, for example, in Remington: The Science and Practice of Pharmacy, Nineteenth Ed (Easton, Pa.: Mack Publishing Company, 1995) ; Hoover, John E., Remington’s Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania 1975; Liberman, H.A.
• the pharmaceutically acceptable excipient is selected from carriers, binders, filling agents, suspending agents, flavoring agents, sweetening agents, disintegrating agents, dispersing agents, surfactants, lubricants, colorants, diluents, solubilizers, moistening agents, plasticizers, stabilizers, penetration enhancers, wetting agents, anti-foaming agents, antioxidants, preservatives, and any combinations thereof.
• the pharmaceutical formulations described herein include, but are not limited to, aqueous liquid dispersions, liquids, gels, syrups, elixirs, slurries, suspensions, self-emulsifying dispersions, solid solutions, liposomal dispersions, aerosols, solid oral dosage forms, powders, immediate release formulations, controlled release formulations, fast melt formulations, tablets, capsules, pills, powders, dragees, effervescent formulations, lyophilized formulations, delayed release formulations, extended release formulations, pulsatile release formulations, multiparticulate formulations, and mixed immediate and controlled release formulations.
• the additional therapeutic agent is administered at the same time as the compound disclosed herein. In some embodiments, the additional therapeutic agent and the compound disclosed herein are administered sequentially. In some embodiments, the additional therapeutic agent is administered less frequently than the compound disclosed herein. In some embodiments, the additional therapeutic agent is administered more frequently than the compound disclosed herein. In some embodiments, the additional therapeutic agent is administered prior than the administration of the compound disclosed herein. In some embodiments, the additional therapeutic agent is administered after the administration of the compound disclosed herein.
• the additional therapeutic agent is an anti-cancer agent.
• the anti-cancer agent is an immune checkpoint inhibitor.
• the immune checkpoint inhibitor is an anti-CTLA-4 (Cytotoxic T lymphocyte antigen 4) antibody, an anti-PD-1 (Programmed death receptor 1) antibody, or an anti-PD-L1 (Programmed death ligand 1) antibody.
• the additional therapeutic agent is an anti-viral agent.
• Example 8 6-fluoro-1-methyl-4- ( (1R, 5S) -8- (5-methylbenzo [d] oxazol-2-yl) -3, 8-diazabicyclo [3.2.1] octan-3-yl) -2-oxo-1, 2-dihydroquinoline-3-carbonitrile
• Example 12 8- (4- (5-fluorobenzo [d] oxazol-2-yl) piperidin-1-yl) -5-methyl-6-oxo-5, 6-dihydro-1, 5-naphthyridine-2-carbonitrile
• Example 14 1-methyl-4- (4- (5-methylbenzo [d] oxazol-2-yl) piperidin-1-yl) -2-oxo-1, 2-dihydropyrido [3, 2-d] pyrimidine-6-carbonitrile
• Example 15 6-chloro-7- (2-methoxyethoxy) -1-methyl-4- (4- (5-methylbenzo [d] oxazol-2-yl) piperidin-1-yl) -1, 5-naphthyridin-2 (1H) -one
• Example 17 6-chloro-7- ( (2-hydroxyethyl) amino) -1-methyl-4- (4- (5-methylbenzo [d] oxazol-2-yl) piperidin-1-yl) -1, 5-naphthyridin-2 (1H) -one
• Example 18 3- ( (2-hydroxyethyl) amino) -5-methyl-8- (4- (5-methylbenzo [d] oxazol-2-yl) piperidin-1-yl) -6-oxo-5, 6-dihydro-1, 5-naphthyridine-2-carbonitrile
• Example 19 7- ( (2-hydroxyethyl) amino) -1-methyl-4- (4- (5-methylbenzo [d] oxazol-2-yl) piperidin-1-yl) -1, 5-naphthyridin-2 (1H) -one
• Example 20 6-chloro-1-methyl-4- (4- (5-methylbenzo [d] oxazol-2-yl) piperidin-1-yl) -7- ( (tetrahydrofuran-3-yl) oxy) -1, 5-naphthyridin-2 (1H) -one
• Example 21 5-methyl-8- (4- (5-methylbenzo [d] oxazol-2-yl) piperidin-1-yl) -6-oxo-3- ( (tetrahydrofuran-3-yl) oxy) -5, 6-dihydro-1, 5-naphthyridine-2-carbonitrile
• Example 25 5-methyl-8- (4- (5-methylbenzo [d] oxazol-2-yl) piperidin-1-yl) -6-oxo-3- ( (tetrahydro-2H-pyran-4-yl) oxy) -5, 6-dihydro-1, 5-naphthyridine-2-carbonitrile
• example 27 The preparation of example 27 referred to the similar procedure as example 26 with the reactant tert-butyl (2-bromoethyl) carbamate replaced by tert-butyl 3-bromopyrrolidine-1-carboxylate.
• LCMS: MS m/z (ESI) [M+H] + 485.2.
• substrate working solution contains 40 ⁇ M ATP (Promega, V915B) and 200 ⁇ M DLG (SignalChem, D430-59) were added to initiate reaction.
• ADP Glo assay reagents (Promega, V9102) were added and luminescence was recorded using an EnVision following the instruction of manual. The percent inhibition was calculated from luminescence by no enzyme control reactions for 100%inhibition and DMSO only reactions for 0%inhibition. The IC 50 value was calculated via a regression analysis of the inhibition rate.
• Example B IL-2 release detection assay
• Isolate Human Pan T cells from PBMC according to T cell isolation kit (Stemcell, 17951) .
• the suspend T cell in RPMI 1640 medium containing 10%FBS, 1%PS and 55 ⁇ M ⁇ -Mer at a density of 3*10 ⁇ 6 cells/well/3ml are seeded into 6 well plate, recovered overnight at 37 °C&5%CO 2 .
• Harvest overnight recovered T cells are suspended in fresh RPMI1640 medium containing 10%FBS, 1%PS and 55 ⁇ M ⁇ -Mer, seeded 1*10 ⁇ 5/well/200 ⁇ l cells into the anti-CD 3 pre-coated 96 well plate. Add dilutions of compounds into the cells and incubate at 37 °C&5%CO 2 for 24 hours.
• IL-2 in cell supernatant was detected by ELISA Kit (R&D, DY202) .
• Activation fold Top activation/DMSO control.
• Activation%at 100nM Activation of non-linear regression equation curve at the concentration of 100nM /DMSO control*100%.
• Example B The data for Example B is shown in Table 4.
• mice CD-1 mice of SPF.
• Source Sino-British SIPPR/BK Lab Animal Ltd, Shanghai. 3 mice were intravenously administrated with given compounds (Formulation: 5%DMSO +10%Solutol + 85%Saline) or orally gavage administrated with given compounds (Formulation: 5%DMSO + 10%Solutol + 85%Saline) .
• the blood samples were taken via cephalic vein at timepoints 0.083 h, 0.25 h, 0.5 h, 1 h, 2 h, 4 h, 8 h and 24 h after intravenous administration or at timepoints 0.25 h, 0.5 h, 1 h, 2 h, 4 h, 6h, 8 h and 24 h after oral gavage administration, 30 ⁇ L/time point.
• Blood samples were placed in tubes containing K2-EDTA and stored on ice until centrifuged. The blood samples were centrifuged at 6800 g for 6 minutes at 2-8 °C within 1h after collected and stored frozen at approximately -80 °C.
• mice PK data of compounds disclosed herein demonstrated much improved PK properties, especially for the AUC 0 ⁇ t and AUC 0 ⁇ as compared with an existing compound (Example 570, in WO2021105117) .

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Epidemiology (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Virology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (10)

Applications Claiming Priority (8)

Related Child Applications (2)

Publications (1)

Family

ID=87883011

Family Applications (1)

Country Status (12)

Cited By (3)

Citations (6)

Family Cites Families (31)

• 2023
  • 2023-03-01 EP EP23762903.5A patent/EP4486741A4/en active Pending
  • 2023-03-01 CN CN202380024550.4A patent/CN118871438A/zh active Pending
  • 2023-03-01 WO PCT/CN2023/078948 patent/WO2023165504A1/en not_active Ceased
  • 2023-03-01 TW TW112107272A patent/TW202342477A/zh unknown
  • 2023-03-01 IL IL315015A patent/IL315015A/en unknown
  • 2023-03-01 AR ARP230100509A patent/AR128669A1/es unknown
  • 2023-03-01 AU AU2023227010A patent/AU2023227010A1/en active Pending
  • 2023-03-01 CA CA3244501A patent/CA3244501A1/en active Pending
  • 2023-03-01 JP JP2024552216A patent/JP2025508971A/ja active Pending
  • 2023-03-01 KR KR1020247032094A patent/KR20240156394A/ko active Pending
  • 2023-10-13 US US18/486,374 patent/US20240051958A1/en active Pending
  • 2023-11-13 US US18/507,595 patent/US12077538B2/en active Active
• 2024
  • 2024-08-29 MX MX2024010648A patent/MX2024010648A/es unknown

Patent Citations (6)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events